萃華珠寶(002731.SZ)收到子公司利潤分配款2500萬元
格隆匯12月30日丨萃華珠寶(002731.SZ)公佈,公司全資子公司深圳市萃華珠寶首飾有限公司(“深圳萃華”)經其股東決定,以其截止到2018年12月31日賬面未分配利潤向公司進行分配,具體分配情況如下:
經容誠會計師事務所(特殊普通合夥)審計,深圳萃華截至2018年12月31日累計未分配利潤為約3.55億元。以此為基礎,深圳萃華向公司分配利潤2500萬元,公司已於2019年12月30日收到深圳萃華的全部分紅款。
此次分紅所得將增加母公司2019年度淨利潤,但不增加公司2019年度合併報表淨利潤。因此,不會影響2019年度公司總體經營業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.